Industry

SYD-101 slows fast-progressing myopia in phase 3 trial

Healio Optometry3d ago1 min read

SYD-101 significantly slowed the progression of myopia in younger children and quick progressors over 36 months, according to a press release from Sydnexis.“The STAR trial provides compelling evidence that low-dose atropine can meaningfully slow myopia progression, particularly in younger children who are progressing quickly,” lead presentation author Tina Rutar, MD, pediatric ophthalmologist and partner at Cataract and Laser Institute of Southern Oregon, told Healio. “These findings help clarify which patients are most likely to benefit and support a more targeted, proactive approach to

Read full article on Healio Optometry

AI Summary

Quick Take

The Phase 3 STAR trial found that SYD-101, a proprietary low-dose atropine formulation, significantly slowed myopia progression over 36 months. The treatment demonstrated particular efficacy in younger children and those identified as fast progressors, supporting a more aggressive intervention strategy for high-risk pediatric patients.

Why It Matters

As myopia prevalence rises globally, the search for standardized, stable pharmaceutical interventions is critical to move beyond the variability of compounded atropine. These 36-month results provide the long-term data necessary to justify early intervention in younger cohorts who are at the highest risk for developing high myopia and associated sight-threatening complications later in life. The findings suggest that clinical decision-making should shift toward a targeted approach, prioritizing 'quick progressors' for pharmaceutical management.

Key Findings

SYD-101 significantly slowed the progression of myopia compared to control groups over a three-year period.
The treatment effect was most pronounced in younger children, a demographic typically associated with higher rates of axial elongation.
Children categorized as 'quick progressors' showed meaningful clinical benefit from the low-dose atropine therapy.
The STAR trial data supports the use of SYD-101 as a proactive tool for managing pediatric refractive error over the long term.

Study Snapshot

Design

Phase 3 clinical trial (STAR trial)

Population

Children with myopia, including those identified as fast progressors

Practice Implications

Clinicians should prioritize younger patients and those showing rapid refractive shifts for low-dose atropine therapy, as these groups appear to be the primary beneficiaries of SYD-101. The 36-month duration of the study provides a level of confidence for maintaining patients on this therapeutic regimen throughout the peak years of myopic progression.

Who's Affected

Pediatric OphthalmologistsOptometristsMyopia Management SpecialistsPediatric Patients

Evidence StrengthStrong

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.